Traders Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading activity on Monday. Investors bought 105,817 call options on the company. This represents an increase of approximately 242% compared to the typical volume of 30,935 call options.

SELLAS Life Sciences Group Price Performance

SLS stock opened at $13.39 on Wednesday. The company’s 50 day simple moving average is $9.31 and its 200-day simple moving average is $6.16. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $15.88. The firm has a market capitalization of $2.63 billion, a PE ratio of -58.22 and a beta of 2.42.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC purchased a new position in SELLAS Life Sciences Group in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets raised its position in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the fourth quarter valued at approximately $38,000. Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the fourth quarter worth approximately $38,000. Finally, California State Teachers Retirement System grew its stake in SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after acquiring an additional 1,709 shares during the period. Hedge funds and other institutional investors own 17.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on SLS shares. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.